This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: August 4, 2006
Last updated: October 30, 2015
Last verified: October 2015

RATIONALE: Vaccines made from cancer cells may help the body build an effective immune response to kill abnormal cells.

PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with myelodysplastic syndromes (MDS).

Condition Intervention Phase
Myelodysplastic Syndromes Biological: GM-K562 cell vaccine Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Safety
  • Hematologic response, defined as achieving a major response in ≥ 1 lineage as described by an erythroid increase > 2 g/dL, platelet increase of 30,000/mm³, or neutrophil increase by 100%
  • Cytogenetic response, defined as normalization of pretreatment cytogenetic abnormalities

Secondary Outcome Measures:
  • Immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) as measured by Elispot assay
  • Correlation of immune response with clinical response (hematologic response, resolution of cytogenetic abnormalities, or decrease in other parameters, such as WT-1 mRNA levels)

Enrollment: 7
Study Start Date: August 2006
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GM-K562 cell vaccine Biological: GM-K562 cell vaccine

Detailed Description:



  • Determine the safety of GM-K562 cell vaccine in patients with myelodysplastic syndromes.
  • Determine the hematologic and cytogenetic response in patients treated with this vaccine.


  • Determine if vaccination with GM-K562 cell vaccine can induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3), as defined by a 30% increase from baseline in specific cytotoxic T-cells measured by Elispot assay, in patients with myelodysplastic syndromes.
  • Determine if immune response correlates with any clinical responses (e.g., hematologic response, resolution of cytogenetic abnormalities, or decrease in other parameters, such as WT-1 mRNA levels).

OUTLINE: This is an open-label study.

Patients receive GM-K562 cell vaccine subcutaneously once in weeks 0, 3, 6, 9, and 17 in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples are collected periodically for correlative and biomarker studies. Samples are analyzed by cytogenetic studies, fluorescent in situ hybridization (FISH), and flow cytometry. Elispot is used to quantify cellular cytotoxic T-cell response to Wilms' tumor-1 (WT-1), survivin, and proteinase 3.

After completion of study treatment, patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Pathologically confirmed myelodysplastic syndromes (MDS), including any of the following:

    • Refractory anemia (RA)
    • RA with ringed sideroblasts
    • Refractory cytopenias with multilineage dysplasia (RCMD)
    • RCMD with ringed sideroblasts
    • RA with excess blasts 1 (5-9% blasts)
    • RA with excess blasts 2 (10-19% blasts)
  • Must have poor-risk MDS, defined by the following:

    • At least 2 lineages involved
    • Unfavorable cytogenetics (i.e., abnormalities of chromosome 5 or 7, 11q23, t[6;9], trisomy 8, inv3, or multiple/complex karyotype)
    • Transfusion requirement of > 2 units of packed red blood cells monthly
  • No chronic myelomonocytic leukemia
  • No transformation to acute myeloid leukemia


  • ECOG performance status 0-2
  • Creatinine < 2.5 mg/dL
  • Bilirubin < 2.5 mg/dL (unless due to Gilbert's syndrome)
  • Room air oxygen saturation ≥ 94% at rest
  • Fertile patients must use effective contraception
  • Negative pregnancy test
  • No other malignancy within the past 5 years except in situ cervical cancer or adequately treated nonmelanoma skin cancer
  • No active autoimmune disease or history of autoimmune disease requiring systemic immunosuppressants including, but not limited to, any of the following:

    • Autoimmune hemolytic anemia
    • Idiopathic thrombocytopenia purpura
    • Inflammatory bowel disease
    • Vasculitis
    • Thyroiditis
    • Rheumatic illnesses
  • No known HIV serum antibody positivity
  • No other disease requiring long-term corticosteroids or other immunosuppressants, such as severe chronic obstructive pulmonary disease or asthma


  • At least 2 weeks since prior systemic corticosteroids or other immunosuppressants (e.g., cyclosporine, azathioprine, tacrolimus, or mycophenolate mofetil)
  • At least 3 weeks since prior growth factors
  • At least 2 months since prior azacitidine for MDS
  • No prior bone marrow or other organ transplantation
  • No concurrent cytotoxic-based therapy for MDS
  • No other concurrent growth factors, including epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00361296

United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: B. Douglas Smith, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00361296     History of Changes
Other Study ID Numbers: J05115, CDR0000491987
P30CA006973 ( U.S. NIH Grant/Contract )
NA_00001530 ( Other Identifier: JHMIRB )
Study First Received: August 4, 2006
Last Updated: October 30, 2015

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
refractory anemia with excess blasts
refractory anemia with ringed sideroblasts
refractory anemia
refractory cytopenia with multilineage dysplasia
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017